AVI BioPharma Announces 2007 Fourth Quarter and Year End Financial Results Conference Call
March 05 2008 - 2:15PM
Business Wire
AVI BioPharma Inc. (Nasdaq:AVII) today announced that the company
will hold a conference call to discuss its 2007 fourth quarter and
full year financial results on Wednesday, March 12, 2008, at 11:00
a.m. Eastern time (8:00 a.m. Pacific time). Individuals interested
in listening to the live conference call may do so by dialing (888)
803-8271 toll free within the United States and Canada, or (706)
634-2467 for international callers. A telephone replay of the
conference call will be available for 48 hours, beginning two hours
after the conclusion of the call, by dialing (800) 642-1687
domestically, or (706) 645-9291 internationally, and entering
reservation number 38222923. The conference call can be heard live
via audio webcast at the company�s Web site: www.avibio.com. A
webcast replay will be available for 14 days. About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NEUGENE� antisense
drugs and ESPRIT exon skipping technology. AVI�s ESPRIT technology
is initially being applied to potential treatments for Duchenne
muscular dystrophy. AVI�s NEUGENE compounds are also designed to
treat cardiovascular restenosis, and aid in coronary artery bypass
graft (CABG) procedures. In addition to targeting specific genes in
the body, AVI�s antiviral program uses NEUGENE antisense compounds
to combat disease by targeting single-stranded RNA viruses,
including Marburg virus, Ebola Zaire virus, and H5N1 avian
influenza virus. More information about AVI is available on the
company�s Web site at http://www.avibio.com. �Safe Harbor�
Statement under the Private Securities Litigation Reform Act of
1995: The statements that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the results of
research and development efforts, the results of preclinical and
clinical testing, the effect of regulation by the FDA and other
agencies, the impact of competitive products, product development,
commercialization and technological difficulties, and other risks
detailed in the company�s Securities and Exchange Commission
filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024